BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 18621530)

  • 1. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors.
    Cuny GD; Yu PB; Laha JK; Xing X; Liu JF; Lai CS; Deng DY; Sachidanandan C; Bloch KD; Peterson RT
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4388-92. PubMed ID: 18621530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe.
    Engers DW; Frist AY; Lindsley CW; Hong CC; Hopkins CR
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3248-52. PubMed ID: 23639540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors.
    Jiang JK; Huang X; Shamim K; Patel PR; Lee A; Wang AQ; Nguyen K; Tawa G; Cuny GD; Yu PB; Zheng W; Xu X; Sanderson P; Huang W
    Bioorg Med Chem Lett; 2018 Nov; 28(20):3356-3362. PubMed ID: 30227946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.
    Williams E; Bullock AN
    Bone; 2018 Apr; 109():251-258. PubMed ID: 28918311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone morphogenetic protein receptors and signal transduction.
    Miyazono K; Kamiya Y; Morikawa M
    J Biochem; 2010 Jan; 147(1):35-51. PubMed ID: 19762341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dorsomorphin and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in C2C12 cells.
    Boergermann JH; Kopf J; Yu PB; Knaus P
    Int J Biochem Cell Biol; 2010 Nov; 42(11):1802-7. PubMed ID: 20691279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BMP signaling balances murine myeloid potential through SMAD-independent p38MAPK and NOTCH pathways.
    Cook BD; Evans T
    Blood; 2014 Jul; 124(3):393-402. PubMed ID: 24894772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism.
    Yu PB; Hong CC; Sachidanandan C; Babitt JL; Deng DY; Hoyng SA; Lin HY; Bloch KD; Peterson RT
    Nat Chem Biol; 2008 Jan; 4(1):33-41. PubMed ID: 18026094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an ALK2-biased BMP type I receptor kinase inhibitor.
    Mohedas AH; Xing X; Armstrong KA; Bullock AN; Cuny GD; Yu PB
    ACS Chem Biol; 2013; 8(6):1291-302. PubMed ID: 23547776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis.
    Derwall M; Malhotra R; Lai CS; Beppu Y; Aikawa E; Seehra JS; Zapol WM; Bloch KD; Yu PB
    Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):613-22. PubMed ID: 22223731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.
    Gillespie P; Goodnow RA; Saha G; Bose G; Moulik K; Zwingelstein C; Myers M; Conde-Knape K; Pietranico-Cole S; So SS
    Bioorg Med Chem Lett; 2014 Feb; 24(3):949-53. PubMed ID: 24412066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dorsomorphin reverses the mesenchymal phenotype of breast cancer initiating cells by inhibition of bone morphogenetic protein signaling.
    Garulli C; Kalogris C; Pietrella L; Bartolacci C; Andreani C; Falconi M; Marchini C; Amici A
    Cell Signal; 2014 Feb; 26(2):352-62. PubMed ID: 24280125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
    Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
    J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The specificities of small molecule inhibitors of the TGFß and BMP pathways.
    Vogt J; Traynor R; Sapkota GP
    Cell Signal; 2011 Nov; 23(11):1831-42. PubMed ID: 21740966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BMP signaling pathway leads to enhanced proliferation in serous ovarian cancer-A potential therapeutic target.
    Peng J; Yoshioka Y; Mandai M; Matsumura N; Baba T; Yamaguchi K; Hamanishi J; Kharma B; Murakami R; Abiko K; Murphy SK; Konishi I
    Mol Carcinog; 2016 Apr; 55(4):335-45. PubMed ID: 25663289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of small organic molecules reveals cooperative TGFβ and BMP regulation of mesothelial cell behaviors.
    Cross EE; Thomason RT; Martinez M; Hopkins CR; Hong CC; Bader DM
    ACS Chem Biol; 2011 Sep; 6(9):952-61. PubMed ID: 21740033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors.
    Hao J; Ho JN; Lewis JA; Karim KA; Daniels RN; Gentry PR; Hopkins CR; Lindsley CW; Hong CC
    ACS Chem Biol; 2010 Feb; 5(2):245-53. PubMed ID: 20020776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors.
    Ducray R; Ballard P; Barlaam BC; Hickinson MD; Kettle JG; Ogilvie DJ; Trigwell CB
    Bioorg Med Chem Lett; 2008 Feb; 18(3):959-62. PubMed ID: 18182285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease.
    Gooding S; Olechnowicz SWZ; Morris EV; Armitage AE; Arezes J; Frost J; Repapi E; Edwards JR; Ashley N; Waugh C; Gray N; Martinez-Hackert E; Lim PJ; Pasricha SR; Knowles H; Mead AJ; Ramasamy K; Drakesmith H; Edwards CM
    Nat Commun; 2019 Oct; 10(1):4533. PubMed ID: 31586071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer.
    Newman JH; Augeri DJ; NeMoyer R; Malhotra J; Langenfeld E; Chesson CB; Dobias NS; Lee MJ; Tarabichi S; Jhawar SR; Bommareddy PK; Marshall S; Sadimin ET; Kerrigan JE; Goedken M; Minerowicz C; Jabbour SK; Li S; Carayannopolous MO; Zloza A; Langenfeld J
    Oncogene; 2018 Jul; 37(27):3672-3685. PubMed ID: 29622797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.